About the Site

Publishing credentials

All original research articles published by Asia Press are made freely and permanently accessible online immediately upon publication. The Asia Press Publishing Group is composed of 1 president and company editor-in-chief, 1 chief financial officer, 3 managing editors, 4 science editors, 2 language editors, and 1 news and views editor. Information about the members of our management team can be found at: http://www.asiapress.asia/index.php/index/about.

Asia Press started its publishing career since 2014, which was initiated upon the publication of the three journals, Journal of NasoPharyngeal Carcinoma, Journal of Minimally Invasive Orthopedics and Journal of Biotherapy. The Journal of NasoPharyngeal Carcinoma was indexed by Western Pacific Region Index Medicus (WPRIM), which is a project of the WHO Western Pacific Regional Office in collaboration with several institutions in its Member States. This is the Region's contribution to the Global Health Library (GHL) initiative which aims to extend to all the benefits of the knowledge that is essential to the fullest attainment of health. In 2015, only 12 journals from China including the Journal of NasoPharyngeal Carcinoma are indexed by WPRIM (http://wprim.whocc.org.cn/local/jt15.jsp).




Pu Jin , MD, Prof., Asia Press, Hong Kong 


Moly Lee, PHD, Asia Press, Hong Kong


Yu Lin, BA, Asia Press, Hong Kong


Yu Lin, BA, Asia Press, Hong Kong

Robun Mao, MD, Asia Press, Hong Kong

Camila Domon, PHD, Asia Press, United States


Lian Li, PHD, Asia Press, Hong Kong

Cheung Low, PHD, Asia Press, Hong Kong

Ying Huang, MD, Asia Press, United States

Anne Alves, PHD, Asia Press, United States


David McConaughey, PHD, Asia Press, Hong Kong

York Lin, MD, Asia Press, China


Xiaofei Mao, BA, Asia Press, Hong Kong


Contact us

Phone: 00852-59797460

E-Mail: admin@asiapress.asia 

 Asia Press Office

1. E18,3/f, Yongda Building, Wen Xian Tung Street 97,Sheung Wan, Hong Kong
2. 368 Riverway, Boston. MA. 02115, United States
3. Room 1307B, Block A, No. 628, Ximen, Sun Yat-Sen University Science Park, Xingang Xi Rd, 135,Guangzhou City , Guangdong Province ,510275, China


Editorial Policies

Ethics and consent

Ethics approval

Research involving human subjects, human material, or human data, must have been performed in accordance with the Declaration of Helsinki and must have been approved by an appropriate ethics committee. A statement detailing this, including the name of the ethics committee and the reference number where appropriate, must appear in all manuscripts reporting such research. If a study has been granted an exemption from requiring ethics approval, this should also be detailed in the manuscript (including the name of the ethics committee that granted the exemption). Further information and documentation to support this should be made available to the Editor on request. Manuscripts may be rejected if the Editor considers that the research has not been carried out within an appropriate ethical framework. In rare cases, the Editor may contact the ethics committee for further information.

Consent to participate

For all research involving human subjects, informed consent to participate in the study should be obtained from participants (or their parent or legal guardian in the case of children under 16) and a statement to this effect should appear in the manuscript.

Research involving animals

Experimental research on vertebrates or any regulated invertebrates must comply with institutional, national, or international guidelines, and where available should have been approved by an appropriate ethics committee. The Basel Declarationoutlines fundamental principles to adhere to when conducting research in animals and the International Council for Laboratory Animal Science (ICLAS) has also published ethical guidelines.

A statement detailing compliance with relevant guidelines (e.g. the revised Animals (Scientific Procedures) Act 1986 in the UK and Directive 2010/63/EU in Europe) and/or ethical approval (including the name of the ethics committee and the reference number where appropriate) must be included in the manuscript. If a study has been granted an exemption from requiring ethics approval, this should also be detailed in the manuscript (including the name of the ethics committee that granted the exemption and the reasons for the exemption). The Editor will take account of animal welfare issues and reserves the right to reject a manuscript, especially if the research involves protocols that are inconsistent with commonly accepted norms of animal research. In rare cases, the Editor may contact the ethics committee for further information.

For experimental studies involving client-owned animals, authors must also document informed consent from the client or owner and adherence to a high standard (best practice) of veterinary care.

Field studies and other non-experimental research on animals must comply with institutional, national, or international guidelines, and where available should have been approved by an appropriate ethics committee. A statement detailing compliance with relevant guidelines and/or appropriate permissions or licences must be included in the manuscript. We recommend that authors comply with the Convention on the Trade in Endangered Species of Wild Fauna and Flora and theIUCN Policy Statement on Research Involving Species at Risk of Extinction.


Clinical trial registration

The Asia Press defines a clinical trial as any research project that prospectively assigns people or a group of people to an intervention, with or without concurrent comparison or control groups, to study the cause-and-effect relationship between a health-related intervention and a health outcome. Health-related interventions are those used to modify a biomedical or health-related outcome; examples include drugs, surgical procedures, devices, behavioral treatments, educational programs, dietary interventions, quality improvement interventions, and process-of-care changes. Health outcomes are any biomedical or health-related measures obtained in patients or participants, including pharmacokinetic measures and adverse events. The Asia Press does not define the timing of first patient enrollment, but best practice dictates registration by the time of first patient consent.

The Asia Press accepts registration in any registry that is a primary register of the WHO International Clinical Trials Registry Platform (ICTRP) or in ClinicalTrials.gov,

The purpose of clinical trial registration is to prevent selective publication and selective reporting of research outcomes, to prevent unnecessary duplication of research effort, to help patients and the public know what trials are planned or ongoing into which they might want to enroll, and to help give ethics review boards considering approval of new studies a view of similar work and data relevant to the research they are considering.


Corrections and retractions

Rarely, it may be necessary for Asia Press to publish corrections to, or retractions of, articles published in its journals, so as to maintain the integrity of the academic record.

Corrections to, or retractions of, published articles will be made by publishing an Erratum or a Retraction article, without altering the original article in any way other than to add a prominent link to the Erratum/Retraction article. The original article remains in the public domain and the subsequent Erratum or Retraction will be widely indexed. In the exceptional event that material is considered to infringe certain rights or is defamatory, we may have to remove that material from our site and archive sites.


Changes to published articles that affect the interpretation and conclusion of the article, but do not fully invalidate the article, will, at the Editor(s)’ discretion, be corrected via publication of an Erratum that is indexed and linked to the original article.


On rare occasions, when the scientific information in an article is substantially undermined, it may be necessary for published articles to be retracted. Asia Press will follow the COPE guidelines in such cases. Retraction articles are indexed and linked to the original article.


Conflict-of-interest statement, statement of informed consent human and animal rights

Conflict-of-Interest Statement 
Statement of Informed Consent 
Human and Animal Rights 
Author Guidelines, which is found in about the ASIA PRESS

Last Update: March 08, 2016

Conflict-of-Interest Statement 
Authors are expected to disclose any commercial or other associations that might pose a conflict of interest in connection with the submitted article, especially Guideline articles, reports of clinical trials and reports on pharmaceutical products or medical devices. All funding sources supporting the work and the institutional or corporate affiliations of the authors should be acknowledged on the title page. Articles are considered for publication on the understanding that neither the article nor its essential substance has been or will be published elsewhere before appearing in the ASIA PRESS. Abstracts and press reports published in connection with scientific meetings are not considered as publications. The authors should specifically confirm in their cover letter that there has been no ghost writing by anyone not named as a co-author of the manuscript. 
Conflict of Interest Statement for ASIA PRESS 

Sample form
I hereby disclose all of my conflicts of interest and other potentially conflicting interests, including specific financial interests and relationships and affiliations relevant to Journal of Nasopharyngeal Carcinoma (eg, employment/affiliation, grants or funding, consultancies, honoraria, stock ownership or stock options, expert testimony, royalties, or patents filed, received, or pending). This applies to the past 5 years and the foreseeable future. I also agree that I will promptly notify the Editor in Chief in writing about any additional potential conflicts of interests that occur. 
I agree that I will disqualify myself from reviewing, editing, or participating in editorial decisions about any ASIA PRESS submission that deals with a matter in which either I or a member of my immediate family (ie, my spouse, domestic partner, or minor children) have direct financial interest or a competing financial interest (eg, employment or affiliation, grants or funding, consultancies, honoraria, stock ownership or stock options, expert testimony, royalties, or patents filed, received, or pending). This also applies to the past 5 years and the foreseeable future. 
I also agree that I will not use any confidential information obtained from my activities with ASIA PRESS to further my own or others financial interests. 
Name (please print) 

Please list any potential conflicts of interest: 

Statement of Informed Consent 
Patients have a right to privacy that should not be infringed without informed consent. Identifying information, including patients' names, initials, or hospital numbers, should not be published in written descriptions, photographs, and pedigrees unless the information is essential for scientific purposes and the patient (or parent or guardian) gives written informed consent for publication. Informed consent for this purpose requires that a patient who is identifiable be shown the manuscript to be published. Authors should identify Individuals who provide writing assistance and disclose the funding source for this assistance. Identifying details should be omitted if they are not essential. Complete anonymity is difficult to achieve, however, and informed consent should be obtained if there is any doubt. For example, masking the eye region in photographs of patients is inadequate protection of anonymity. If identifying characteristics are altered to protect anonymity, such as in genetic pedigrees, authors should provide assurance that alterations do not distort scientific meaning and editors should so note. When informed consent has been obtained it should be indicated in the published article. 

Human and animal rights 
Depending on the nature of the regarding research, manuscripts submitted for publication in the ASIA PRESS must contain a statement to the effect that the concerning legally binding ethical standards have been met. Authors are required to check if any of the below statements applies to their submitted work and if necessary, to tick the relevant box and sign the form accordingly. 
Reports of animal experiments must state that the "Principles of Laboratory Animal Care" (NIH publication No. 85- 23, revised 1985) were followed. Moreover authors may have to state that specific national laws (e.g., the current version of the German Law on the Protection of Animals) have been observed, too. 
All human studies must state that they have been approved by the appropriate ethics committee and have therefore been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki. The author hereby declares that the research documented in the submitted manuscript has been carried out in accordance with the above stated ethical standards.


Advertising policies 
1. All advertisements are subject to approval of the Asia Press(Publisher), which reserves the right to reject or cancel any ad at any time. Asia Press does not endorse the products and services of its advertisers.

2. All advertisements are accepted and published by Publisher on the warranty of the agency and advertiser that both are authorized to publish the entire contents and subject matter of the advertisement.

3. In consideration of publication of an advertisement, the advertiser and the agency, jointly and severally, agree to indemnify and hold harmless Publisher, its officers, agents and employees against expenses (including legal fees) and losses resulting from the publication of the contents of the advertisement, including, without limitation, claims or suits for libel, violation of privacy, copyright infringement or plagiarism.

4. Publisher will not be liable for any failure to publish any advertisement accepted by Publisher; however, Publisher shall use its reasonable efforts to place such advertisement in subsequent available space.

5. All advertisements must clearly and prominently identify the advertiser by trademark or signature.
6. Any references to Publisher or its products or services in advertisements, promotional material or merchandising by the advertiser or agency is subject to Publisher’s written approval for such use.

7. All advertising contract position clauses are treated as requests. Publisher cannot guarantee fixed positioning.

8. Publisher is not responsible for incidental or consequential damage for errors in displaying or printing an ad.

9. Publisher may change the terms set forth herein at any time, provided that no such change applies to ads whose closing date precedes the announcement of the change.

10. Publisher will not be bound by any condition, printed or otherwise, appearing on any insertion order or copy instructions when such conditions conflict with the conditions set forth in this rate card.

11. In the event of nonpayment, Publisher reserves the right to hold advertiser and/or its advertising agency jointly and severally liable for such monies as are past due and payable to Publisher.

12. Advertiser represents and warrants that all advertisements and pharmaceutical products they advertise are compliant with all applicable laws, rules, and regulations in the country where the advertisement will be seen. Advertisements for pharmaceutical products (including NDA products) that are subject to US Food and Drug Administration (FDA) oversight must comply with FDA regulations regarding advertising and promotion.

13. Any use of Publisher’s trademarks (including the New England Journal of Medicine and its logo design, NEJM, and NEJM Group) or copyrighted material for links to and from a Publisher website must be approved in advance by Publisher. Publisher does not endorse or support any product or organization linked to its website, nor is Publisher responsible for the content of any website promoted in any advertisement appearing at a Publisher website.

14. All advertisements at www.Asiapress.asia served on article pages are served on a random basis, in rotation with Editorial Group advertising and recruitment advertising. The random placement algorithm does not permit any commercial ad to be targeted to any specific article or any specific user or groups of users.  Advertisers have no advance knowledge of and no control over ad placement.  Neither the Publisher nor its publications endorse any company, product, or service.

Recruitment ads must be nondiscriminatory and comply with all applicable laws and regulations. Ads that discriminate against applicants based on sex, age, race, religion, marital status or physical handicap will not be accepted. Non-US recruitment advertisers are required to confirm in writing that they are equal opportunity employers.

Online cancellation policies

Advertiser may cancel the entire Insertion Order, or any portion thereof, as follows:

Run-Of-Site Banner Programs:
On written notice to Publisher given 21 or more days before the start date. With cancellations inside 21 days of the start date, advertiser will be responsible for 50% of the Insertion Order amount that was reserved for delivery.

Flat fee-based or fixed placement programs (including, but not limited to, Roadblocks, Specialty Packs, NEJM eTOC and other Sponsorships and Physicians First Watch and Journal Watch email products):
On written notice to Publisher given 30 or more days before the start date. With cancellations inside 30 days of the start date, advertiser will be responsible for 50% of the IO amount that was reserved for delivery.


Advertising Policies for print and web publications :

The Asia Press accepts nonprofit advertising in certain of its publications including (but not limited to) professional journals and web sites, meeting and convention publications, and direct-to-patient/consumer publications and web sites.


Peer review process


About this Publishing System